US EditionInsulet sales increase 22% in 2025, Q4 performance beats Street
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Insulet sales increase 22% in 2025, Q4 performance beats Street
Insulet (Nasdaq:PODD) shares dipped after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of PODD fell 2.7% to $280.66 apiece in post-market trading today. The Acton, Massachusetts-based automated insulin delivery technology maker reported profits of $100.7 million. That equals $1.39 per share on sales of $597.5 million for the three months ended Dec. 31, 2024. Insulet recorded a 2.5% bottom-line slide …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
